India's national highway authority to bid out 124 road projects worth ₹3.4 lakh crore in FY26
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
The National Highways Authority of India (NHAI) plans to open bids for 124 highway and expressway projects worth ₹3.4 lakh crore in 2025–26. The combined length of these upcoming road projects is estimated at 6,376 kilometres, reported PTI on Friday.Among the major corridors in the pipeline is the Gorakhpur–Kishanganj–Siliguri stretch (476 km), which will be developed under the Hybrid Annuity Model (HAM). Another key route, the Tharad–Deesa–Mehsana–Ahmedabad package-1 (106 km), will be tendered under the Build-Operate-Transfer (BOT) model.The NHAI also plans capacity augmentation work on the Pampore (Srinagar) to Qazigund section of NH-44 (48 km). This will include the construction of service roads and grade-separated structures and will be awarded under the Engineering Procurement and Construction (EPC) model.Highway development in India typically follows one of three models: BOT, HAM, and EPC. BOT projects usually have a concession period of 15 to 20 years, during which the private developer maintains the road. In the HAM model, the typical concession period is 15 years, and the concessionaire is also responsible for maintenance.EPC contracts, in contrast, come with fixed maintenance obligations after completion , five years for bituminous roads and ten years for concrete stretches.These upcoming tenders are part of NHAI's broader push to ramp up highway infrastructure and attract private participation across funding models.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
28 minutes ago
- Time of India
Income Tax refunds jump 474% since 2013-14, issuance time improves in past 11 years
Synopsis India's Income Tax refunds have surged by 474% over the past 11 years, reaching Rs 4.77 lakh crore in 2024-25, outpacing the 274% growth in gross tax collections. The processing time for refunds has significantly decreased from 93 days in 2013 to just 17 days in 2024. This improvement is attributed to enhanced tax administration and digital infrastructure.
Time of India
30 minutes ago
- Time of India
Tech Park: Karnataka CM Siddaramaiah's meeting on Tuesday to decide on farmers offer to sell their land for Rs 3.5 cr per acre
Protesting farmers from Devanahalli have offered to give up 449 acres near the international airport for the proposed high-tech park if the government fixes a rate of Rs 3.5 crore per acre . The state government will take a decision on the demand at July 15 meeting to be chaired by Chief Minister Siddaramaiah. Industries Minister MB Patil , speaking to the media on Sunday, said he hoped a solution would emerge on Tuesday. The farmers are demanding higher compensation, suitable jobs for locals who are giving up their lands and declaring the surrounding areas as a yellow zone. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Villas In Dubai | Search Ads Get Rates Patil said the government was keen to balance the interests of farmers with the need for industrialization. There are also demands from local protestors to preserve the agricultural lands, which has led to a thinking in the government to declare the region as a green zone. The government, the minister added, was aware not all protesters were genuine farmers and some of them have already entered into agreements with big builders agreeing to sell their lands for real estate. Live Events Farmers of Channarayapatna hobli in Bengaluru rural district have been on a protest seeking to stall the acquisition. The previous BJP regime had, on August 27, 2021, issued a preliminary notification proposing acquisition of 1,772.2 acres of land from 13 villages in Channarayapatna hobli. Patil, the industries minister, had said last month that the process of acquiring the remaining 1,232 acres of land will go on as planned before.
Economic Times
31 minutes ago
- Economic Times
Cipla eyes entry into India's weight management market amid rising demand and global competition
Synopsis Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also strengthening its central nervous system portfolio through strategic in-licensing deals and acquisitions, particularly in ADHD and Parkinson's disease. The company is also focusing on innovation-led solutions to combat antimicrobial resistance and aims to be a global, patient-centric healthcare leader. Agencies Representative image Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has Mumbai-based firm is also strengthening its presence in the central nervous system (CNS) therapeutic area, he stated in his address to shareholders in the company's Annual Report for 2024-25."Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra domestic drug firms are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in the country. Danish firm Novo Nordisk has also launched its anti-obesity drug Wegovy, indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular the CNS segment, Cipla has successfully in-licensed Sanofi's India CNS product range, including Frisium, a leading brand in the anti-epileptic category, Vohra informed shareholders."Building on this momentum, we aim to pursue similar in-licensing deals or acquisitions in niche indications of attention deficit hyperactivity disorder (ADHD) and Parkinson's disease," he company is equally committed to addressing the global crisis of antimicrobial resistance (AMR), he added."Our AMR portfolio is evolving from volume-based to innovation-led, with four novel products in development," Vohra noted that the company's ambition is to be a global, innovation-led, patient-centric healthcare company that creates long-term value through science, empathy, and sustainability."We will continue to invest in big brands, strategic alliances, digital infrastructure, and next-generation therapies, while remaining rooted in our founding values of care and compassion," Vohra stated. Cipla's consolidated revenue stood at Rs 27,548 crore in FY25. Its consolidated net profit rose to Rs 5,272 crore during the period.
